Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 8/20 | 0.54 |
| ▸ | AURKA | O14965 | 3/20 | 0.54 |
| ▸ | JAK2 | O60674 | 3/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.54 |
| ▸ | FLT1 | P17948 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | CLK2 | P49760 | 3/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.54 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.54 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.54 |
| ▸ | IGF1R | P08069 | 2/20 | 0.54 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.54 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7921128 | 0.80 | MET (0.46) | ITKMETBTKPRMT5WDR77 | |
| SCHEMBL1565867 | 0.77 | DYRK1A (0.54) | ITKAURKAJAK2MAP4K4FGFR1 | |
| SCHEMBL1564760 | 0.77 | ITK (0.54) | ITKAURKAJAK2MAP4K4FGFR1 | |
| SCHEMBL25841381 | 0.77 | MET (0.43) | ITKMETBTKPRMT5WDR77 | |
| SCHEMBL68662 | 0.77 | DYRK1A (0.58) | ITKAURKAJAK2MAP4K4FGFR1 | |
| SCHEMBL14883424 | 0.77 | JAK2 (0.54) | ITKJAK2METBTKPRMT5 | |
| SCHEMBL10269012 | 0.77 | MET (0.43) | ITKDYRK1AMETBTKPRMT5 | |
| SCHEMBL1564507 | 0.77 | GSK3B (0.56) | ITKAURKAJAK2MAP4K4FGFR1 | |
| SCHEMBL11968456 | 0.77 | DYRK1A (0.54) | ITKAURKAJAK2MAP4K4FGFR1 | |
| SCHEMBL14041214 | 0.77 | MET (0.43) | ITKMETBTKPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12486264-B2 | Bicyclic HPK1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-02 | — | — | US | disclosed |
| EP-4605395-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | Dong-A ST Co., Ltd. (KR) | 2025-08-27 | — | — | EP | disclosed |
| EP-3947373-B1 | BICYCLIC HPK1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-14 | — | — | EP | disclosed |
| EP-4267574-B1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2024256988-A1 | SMARCA2 DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| CN-118488947-A | Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-12043632-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2007106236-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486264-B2 | Bicyclic HPK1 inhibitors | PCK1, PGK1, PDXK | ITK 1800/4885AURKA 972/4885JAK2 3717/4885 |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | ITK 1838/4885AURKA 461/4885JAK2 214/4885 |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | API5, MAP3K5, MAP3K7 | ITK 1385/4885AURKA 1221/4885JAK2 551/4885 |
| US-12043632-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | ITK 1760/4885AURKA 805/4885JAK2 1/4885 |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | ITK 486/4885AURKA 153/4885JAK2 344/4885 |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | AXL, ERBB2, ERBB3 | ITK 705/4885AURKA 1021/4885JAK2 119/4885 |
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | ITK 4697/4885AURKA 4112/4885JAK2 898/4885 |
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | ITK 3364/4885AURKA 2084/4885JAK2 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.